Can silencers add benefit in ATTR-CM?

Detailed data from Wainua’s CARDIO-TTRansform study showed that in patients on TTR stabilizers at baseline, adding the TTR-targeting antisense oligo from Ionis and AZ led to worse outcomes than treatment with stabilizers alone.

Partners Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and AstraZeneca plc (LSE:AZN; NYSE:AZN) had already announced in July that Wainua eplontersen missed the primary endpoint in the Phase III trial to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a major setback for a planned future revenue driver for both companies...